Stockscreener 앱 받기
69.30
2.94%
-2.10
전일 마감가:
$71.40
열려 있는:
$70.62
하루 거래량:
673.54K
Relative Volume:
0.40
시가총액:
$5.78B
수익:
$1.73B
순이익/손실:
$682.64M
주가수익비율:
8.9577
EPS:
7.7364
순현금흐름:
$411.18M
1주 성능:
-1.13%
1개월 성능:
+0.29%
6개월 성능:
+7.79%
1년 성능:
+19.46%
1일 변동 폭
$69.26
$71.41
1주일 범위
$68.75
$72.68
52주 변동 폭
$56.51
$90.87
PTC 테라퓨틱스 Stock (PTCT) Company Profile
명칭
Ptc Therapeutics Inc
전화
(908) 222-7000
주소
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
69.30 | 5.89B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
PTC 테라퓨틱스 Stock (PTCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-12-01 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-17 | 개시 | Truist | Buy |
| 2025-05-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-07 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-11 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 개시 | Scotiabank | Sector Perform |
| 2024-12-13 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-08-26 | 재개 | UBS | Buy |
| 2024-05-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-10-30 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-27 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-10-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-09-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-09-15 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2023-03-17 | 개시 | SVB Securities | Market Perform |
| 2022-12-14 | 개시 | Goldman | Sell |
| 2022-09-12 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-10-18 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-29 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-30 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-04-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-05-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 개시 | Bernstein | Outperform |
| 2018-10-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-06-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 재개 | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-10-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
PTC 테라퓨틱스 주식(PTCT)의 최신 뉴스
PTC Therapeutics (NASDAQ:PTCT) Director Sells 12,500 Shares - MarketBeat
PTC Therapeutics (NASDAQ: PTCT) director sells 25,000 shares in 10b5-1 trade - Stock Titan
PTC Therapeutics (NASDAQ:PTCT) Gains Attention After Results - Kalkine Media
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
The Bull Case For PTC Therapeutics (PTCT) Could Change Following Renal Data Progress For ST-920 - Sahm
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,813 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ: PTCT) CLO sells 2,813 shares under 10b5-1 plan - Stock Titan
PTC Therapeutics (NASDAQ: PTCT) holder plans 50,000-share resale - Stock Titan
PTC Therapeutics, Inc. (PTCT) Stock Price, News, Quote & History - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
PTC Therapeutics (NASDAQ: PTCT) insider lines up $201,692 share sale - Stock Titan
Price to earnings forward of PTC Therapeutics, Inc. – BX:P91 - TradingView
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal - MarketBeat
The week in pharma: action, reaction and insight – week to August 14, 2026 - The Pharma Letter
Assenagon Asset Management S.A. Has $563,000 Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Is Maintained at Overweight by Barclays - Moomoo
Walleye Capital LLC Takes $1.59 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity' - Sahm
PTCT Maintained by Barclays -- Price Target Raised to $122 - GuruFocus
PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy - Dealbreaker
Bank of America Securities Reaffirms Their Buy Rating on PTC Therapeutics (PTCT) - The Globe and Mail
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $130 - Moomoo
PTC takes a chance on Sangamo’s Fabry disease gene therapy - BioPharma Dive
PTCT Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $109 - GuruFocus
PTC to Acquire Sangamo’s Fabry Disease Gene Therapy - Contract Pharma
PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy - TipRanks
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale - BioSpace
Form 8K PTC Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
PTC to expand rare disease portfolio with ST-920 buy - The Pharma Letter
PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction - Endpoints News
PTC THERAPEUTICS, INC. : JEFFERIES RAISES TARGET PRICE TO $115 FROM $100 - Bitget
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo Finance
Bankrupt Sangamo scores at least $163 million in asset sale, which had two big winners - The Business Journals
PTC Therapeutics to acquire Fabry disease gene therapy ST-920 - Investing.com
PTC Therapeutics to acquire Fabry disease gene therapy ST-920 By Investing.com - Investing.com Nigeria
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program - PR Newswire
How Ptc Therapeutics Inc. (PTCT) Affects Rotational Strategy Timing - Stock Traders Daily
Why PTC Therapeutics (PTCT) Is Up 6.7% After Profit Beat, Higher Guidance And New Board Appointment - simplywall.st
Is PTC Therapeutics (PTCT) Undervalued As Profit And Revenue Guidance Jumped? - Sahm
Don't Ignore The Insider Selling In PTC Therapeutics - Moomoo
Have PTC Therapeutics Insiders Been Selling Stock? - simplywall.st
Zacks Research Downgrades PTC Therapeutics (NASDAQ:PTCT) to Hold - MarketBeat
PTC Therapeutics Inc (PTCT) Stock News Today - TradingKey
PTC Therapeutics CEO Klein sells $705,722 in company stock By Investing.com - Investing.com South Africa
PTC Therapeutics Inc (PTCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PTC Therapeutics CEO Klein sells $705,722 in company stock - Investing.com
Bank of America Corp DE Raises Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. $PTCT Stock Position Lifted by California State Teachers Retirement System - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CEO Sells 10,292 Shares of Stock - MarketBeat
PTC Therapeutics (PTCT) CEO sells 10,292 shares to cover taxes - Stock Titan
PTC Therapeutics (PTCT) Stock Fair Value Edges Higher After Analyst Target Increases - finance.yahoo.com
PTC 테라퓨틱스 (PTCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
PTC 테라퓨틱스 주식 (PTCT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SCHMERTZLER MICHAEL | Director |
Aug 27 '26 |
Sale |
71.58 |
12,500 |
894,784 |
1,336,594 |
| SCHMERTZLER MICHAEL | Director |
Aug 19 '26 |
Sale |
73.32 |
12,500 |
916,554 |
1,374,094 |
| SCHMERTZLER MICHAEL | Director |
Aug 20 '26 |
Sale |
71.11 |
12,500 |
888,858 |
1,361,594 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Aug 17 '26 |
Option Exercise |
25.69 |
2,813 |
72,266 |
108,085 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Aug 17 '26 |
Sale |
72.57 |
2,813 |
204,127 |
105,272 |
0.86%
0.31%
자본화:
|
볼륨(24시간):